Home
Xbrane Bioscience

Xbrane Bioscience Market Share Analysis for May 2026

Industry: N/A

Domainxbrane.com

Year Founded2008

Employees51 - 200

Annual Revenue$15M - $25M

Xbrane Bioscience

Xbrane Bioscience (including company regionals)

xbrane.com

See more website traffic and engagement information

Xbrane Bioscience Revenue up to May 2026 is 15M - 25M

revenue generated by Xbrane Bioscience top domains

Xbrane Bioscience top domains revenue over 3 years

Revenue for Xbrane Bioscience top domains

xbrane.com15M - 25M

See more with Sales Intelligence

Total visits to Xbrane Bioscience's top domains

Understand Xbrane Bioscience market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

xbrane.com1.2K

See more with Sales Intelligence

Avg. visit duration in Xbrane Bioscience's top domains

Analyze Xbrane Bioscience engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

xbrane.com--

See more with Sales Intelligence

Avg. pageviews on Xbrane Bioscience's top domains

See how Xbrane Bioscience keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

xbrane.com1.14

See more with Sales Intelligence

Xbrane Bioscience top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Xbrane Bioscience

These are the website technologies, by industry, used by Xbrane Bioscience top domains

Audio Video Media (5)

YouTube

Conversion & Analytics (5)

Google Analytics

Widget (3)

Twemoji

Advertising (2)

Google Adsense

More Technologies

8

See all

News & Signals from Xbrane Bioscience

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsXbrane Biopharma AB sold assets to Alvotech in the amount of $29.3M on Mar 1st '25.In March 2025, Alvotech acquired Xbrane Biopharma's Swedish research and development operations and its certolizumab pegol biosimilar candidate XB003, adding a new clinical-stage asset and an R\&D facility for approximately SEK 275 million (roughly USD 27 to 29 million).

NewsXbrane Biopharma AB partnered with Joinnbio on Jun 11th '26.Xbrane Biopharma AB and JOINN Biologics US Inc. enter strategic partnership to develop Xdarzane - Xbrane ́s biosimilar candidate to darzalex(r)(daratumumab).